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Abstract
Background: Severe acute respiratory syndrome (SARS) emerged in later February 2003, as a
new epidemic form of life-threatening infection caused by a novel coronavirus. However, the
immune-pathogenesis of SARS is poorly understood. To understand the host response to this
pathogen, we investigated the gene expression profiles of peripheral blood mononuclear cells
(PBMCs) derived from SARS patients, and compared with healthy controls.
Results: The number of differentially expressed genes was found to be 186 under stringent filtering
criteria of microarray data analysis. Several genes were highly up-regulated in patients with SARS,
such as, the genes coding for Lactoferrin, S100A9 and Lipocalin 2. The real-time PCR method
verified the results of the gene array analysis and showed that those genes that were up-regulated
as determined by microarray analysis were also found to be comparatively up-regulated by real-
time PCR analysis.
Conclusions:  This differential gene expression profiling of PBMCs from patients with SARS
strongly suggests that the response of SARS affected patients seems to be mainly an innate
inflammatory response, rather than a specific immune response against a viral infection, as we
observed a complete lack of cytokine genes usually triggered during a viral infection. Our study
shows for the first time how the immune system responds to the SARS infection, and opens new
possibilities for designing new diagnostics and treatments for this new life-threatening disease.
Background
Severe acute respiratory syndrome (SARS) emerged in
2003, as a new epidemic form of life-threatening infection
[1]. As of September 2003, there were 8098 cases of SARS
from 29 countries with 774 deaths (WHO). SARS is char-
acterized by high fever, malaise, rigors, headache, dry
cough, and progression to interstitial infiltration in lungs
with eventual mortality of greater than 10% in many
countries [2]. SARS has been shown to be caused by a
novel coronavirus; SARS-CoV, with genome sequences
recently published [3-7]. However, the pathogenesis of
SARS is poorly understood. Major hematological features
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of this disease are lymphopenia, transient thrombocyto-
penia, and normal neutrophil and monocyte counts [8]. It
has been shown that SARS coronavirus infects and repli-
cates in a wide variety of host cells, including PBMCs, in
susceptible animals and human beings [9,10]. Hence, to
understand the host response to this pathogen, we pro-
filed the gene expression patterns of peripheral blood
mononuclear cells (PBMC) from SARS patients, com-
pared to healthy controls using oligo nucleotide microar-
rays. We found that in the PBMC from SARS patients a
number of genes were differentially expressed, as com-
pared to healthy controls, including immune-related
genes and these genes are not the typical ones expected in
a viral infection.
During a viral infection, most cell types in the body
respond by secreting high levels of type 1 interferons
(IFN-α and IFN-β) [11]. IFN-α/β can directly induce anti-
viral activities in neighboring cells, preventing viral spread
by increasing the resistance of uninfected cells toward the
virus. Moreover, these IFNs can activate Natural Killer
(NK) cells mediated cytotoxity toward virus-infected cells
[11,12], and there is accumulating evidence that IFN-α/β
contribute to driving the adaptive-immune response in
the T helper cell type 1 (Th1) direction, via stimulation of
IFN-γ expression [12]. NK cells can produce IFN-γ [13],
which activates leukocytes, such as monocytes/macro-
phages, that, in turn, participate in the antiviral responses
by producing free radicals and proinflammatory cytokines
such as TNF-α [13]. During the response to viral infec-
tions, a key role is played by the expansion and activation
of CD4+ and CD8+ T cells, which are central to the antivi-
ral immunity, including their capability to inhibit replica-
tion and clear the infection. CD8+ cells have a direct
effector role through cytotoxic T lymphocyte mediated
lysis, and cytokine and chemokine production [14]. The
role of CD4+ T cells in antiviral immunity is highly
dependent on production of cytokines, notably IFN-γ
[15], and the cytolytic activity exerted by a subset of CD4+
T cells [16]. Activation, coordination, and regulation of
the above-described antiviral responses are mediated by
complex mechanisms, where cytokines play important
roles. However, to our surprise, we found that the
patients' response of SARS appears to be mainly an innate
inflammatory response, rather than a specific immune
response against a viral infection. There is no significant
level of up-regulation of MHC-I genes, neither for major
cytokines including IFNs, nor for genes involved in com-
plement mediated cytolysis, suggesting that the immune
response against SARS-CoV may be different from other
viral infections.
Results and discussion
To study the differential immune-gene expression pat-
terns induced by SARS coronavirus, PBMCs from patients
with SARS and normal subjects were examined using
microarray technology. We shooed to use PBMCs as these
cells are more easily obtained from patients compared to
other infected tissues, and the SARS-CoV has recently
been shown to infect PBMCs [9,10]. The method of global
gene expression analysis using oligonucleotide microar-
rays has proven to be a sensitive method to develop and
refine the molecular determinants of several human disor-
ders, including cancer and autoimmune diseases, and has
provided us with signatures of the immune response [17].
Using this technology, complemented with powerful ana-
lytical methods, we compared the gene expression profiles
of PBMC from a series of SARS patients with those of
healthy donors. To ensure the reliability and reproducibil-
ity of the microarray analysis, Pearson Correlation factors
using the signal from all the normal samples were calcu-
lated. All four control arrays have Pearson correlation
coefficients (r) of >0.95, which suggests an excellent
reproducibility among individual arrays in the same
experiment and between normal control experiments.
We analyzed the expression pattern of over ~8,700 genes
from the PBMCs of 10 SARS patients, and compared the
expression patterns with healthy control samples. Stu-
dent's unpaired T-test (P < 0.01) was performed and sig-
nificant genes were selected. Cluster analysis was
performed to find distinct groups of genes that were sig-
nificantly changed. The criteria used for cluster analysis is
different from filter criteria used for differentially
expressed genes. 248 genes were selected for Hierarchical
clustering (Figure 1) which includes all the 186 differen-
tially expressed genes. The severity of the disease does not
seem to change the genetic profile of the PBMCs: 5 of our
patients were in intensive care, whereas the other 5
patients did not require intensive care, at the time the
blood was taken. However, no substantial gene-expres-
sion differences were observed that could correlate to dis-
ease severity.
To our surprise, the expression of genes coding for
cytokines was completely absent, and the immune-related
genes which were overexpressed are usually associated
with innate-immune response against bacterial infection
and not against a viral infection (Table 1). Several genes
were highly up-regulated in patients with SARS, such as,
genes coding for Lactoferrin, S100A9 and Lipocalin 2
among others (Table 1). Lactoferrin is a 78- to 80-kDa
glycoprotein synthesized by glandular epithelial cells and
mature neutrophils, frequently used as a marker for neu-
trophil degranulation at sites of inflammation, having
well recognized bacteristatic and bactericidal properties
[18]. It is now clear that the biological actions of lactofer-
rin are not restricted to its bacteristatic and bactericidal
properties. Indeed, a wide array of actions has been
reported for lactoferrin, including enhancing NK cellBMC Immunology 2005, 6:2 http://www.biomedcentral.com/1471-2172/6/2
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Clustering and distribution of differentially expressed genes Figure 1
Clustering and distribution of differentially expressed genes. A. Hierarchical clustering of gene expression data from 
PBMCs from 10 SARS patients showing different classes of gene expression profiles. Each row represents a separate gene and 
each column a separate SARS patient. 248 genes have been selected for this analysis which is described in methods. The 
expression index for each gene (rows) in each sample (column) is indicated by a color code. The color scale ranges from satu-
rated green for log ratios -3.0 and above to saturated red for log ratios 3.0 and above. Red indicates increased gene expression 
levels, whereas green indicates decreased levels compared with normal samples. B. Pie chart showing the percentage distribu-
tion of the differentially expressed genes from the PBMCs of 10 SARS patients.
A
Percentage of differentially expressed 
genes
32%
9%
32%
27%
Upregulated Immune-response genes
Downregulated Immune-response genes
Upregulated genes involved in
homeostasis and cell growth
Miscellaneous
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Table 1: Immune-response related genes which were found to be significantly up-regulated in PBMCs of SARS patients. Level of 
expression is expressed in Fold change (average of fold changes of ten patients, S1-S10) as compared to that of control samples from 
normal human subjects (C1-C4).
Gen Bank ID Description Gene name Fold change (S1-S10)
NM_002343.1 Lactotransferrin LTF 149.63
M33326.1 Carcinoembryonic antigen-related cell adhesion molecule 8 CEACAM8 97.29
NM_005564.1 Lipocalin 2 LCN2 80.40
NM_004660.2 S100 calcium binding protein A9 S100A9 65.39
NM_001725.1 Bactericidal permeability-increasing protein BPI 49.94
NM_005091.1 Peptidoglycan recognition protein PGLYRP 47.86
NM_001925.1 Defensin alpha 4 DEFA4 46.88
U19970.1 Antimicrobial LPS-binding protein CAP18 CAMP 43.36
NM_005980.1 S100 calcium-binding protein P S100P 39.52
NM_005143.1 Haptoglobin HP 34.78
NM_004084.2 Defensin alpha 1 DEFA1 29.51
NM_006865.1 Leukocyte immunoglobulin-like receptor, subfamily A, member 3 LILRA3 19.43
NM_002870.1 RAS oncogene family (RAB13) RAB13 14.85
NM_003064.1 Secretory leukocyte protease inhibitor SLPI 11.35
NM_000265.1 Neutrophil cytosolic factor 1 NCF1 11.30
NM_000634.1 Interleukin 8 receptor alpha IL8RA 10.85
AL138717 Rag D protein RAGD 7.84
BG327863 CD24 antigen CD24 7.69
NM_000419.2 integrin, alpha 2b (antigen CD41B) ITGA2B 5.50
NM_001828.3 Charot-Leyden crystal protein CLC 5.47
AI078167 Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha NFKBIA 5.21
NM_005621.1 S100 calcium-binding protein A12 S100A12 5.05
NM_003255.2 Tissue inhibitor of metalloproteinase 2 TIMP2 4.93
NM_002029.1 Formyl peptide receptor 1 FPR1 4.59
NM_005384.1 Nuclear factor, interleukin 3 regulated NFIL3 4.50
M25915.1 Complement cytolysis inhibitor (CLI) CLU 4.07
NM_002965.2 S100 calcium-binding protein A9 S100A9 4.05
NM_014214.1 Inositol (myo)-1(or 4)-monophosphatase 2 IMPA2 3.95
NM_003189.1 T-cell acute lymphocytic leukemia 1 TAL1 3.94
U62027.1 C3a receptor C3AR1 3.83
NM_001150 Alanyl (membrane) aminopeptidase ANPEP 3.83
BE789881 RAS oncogene family RAB31 3.75
NM_001769.1 CD9 antigen (p24) CD9 3.73
NM_014358.1 C-type lectin, superfamily member 9 CLECSF9 3.53
NM_006834.1 RAS oncogene family member (RAB32) RAB32 3.40
J04162.1 Leukocyte IgG receptor (Fc-gamma-R) FCGR3A 3.32
NM_006866.1 Lleukocyte immunoglobulin-like receptor, subfamily A2 LILRA2 3.30
U41070.1 Leukotriene b4 receptor LTB4R 3.23
NM_000632.2 Integrin, alpha M ITGAM 3.20
BC003393.1 Phosphoinositide-3-kinase, catalytic, beta polypeptide PIK3CB 3.13
NM_002432.1 Myeloid cell nuclear differentiation antigen MNDA 3.08
NM_003264.1 Toll-like receptor 2 TLR2 3.05
NM_004475.1 Flotillin 2 FLOT2 3.04
NM_003461.1 Zyxin ZYX 2.96
NM_003897.1 Immediate early response 3 IER3 2.91
AF119873.1 Serine (or cysteine) proteinase inhibitor alpha-1 SERPINA1 2.87
NM_016205.1 Platelet derived growth factor C PDGFC 2.74
NM_005479.1 Frequently rearranged in advanced T-cell lymphomas FRAT1 2.72
AV756141 Colony stimulating factor 2 receptor beta CSF2RB 2.71
NM_006019.1 T-cell, immune regulator 1 TCIRG1 2.59
J02959.1 Leukotriene A-4 hydrolase LTA4H 2.59
BC004188.1 Tubulin, beta, 2 TUBB2 2.57
NM_001780.1 CD63 antigen CD63 2.53
NM_003254.1 Tissue inhibitor of metalloproteinase 1 TIMP1 2.37
AF070673.1 Stannin SNN 2.35
BC003570.1 Similar to vesicle-associated membrane protein 3 VAMP3 2.31BMC Immunology 2005, 6:2 http://www.biomedcentral.com/1471-2172/6/2
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activity, as well as stimulating neutrophil aggregation and
adhesion [18]. The myeloid-related proteins, S100A8,
S100A9, and S100A12 have been shown to regulate lym-
phocyte, monocyte, and neutrophil migration and are
found in the extracellular milieu during infections and
inflammatory episodes [19,20]. The high levels of serum
S100A8/A9 in chronic inflammatory pathologies such as
rheumatoid arthritis and inflammatory bowel disease, as
well as during bronchitis and tuberculosis [20], suggest
that they might play a role in inflammatory reactions.
Lipocalins are a family of small, secreted proteins, which
have little amino acid sequence homology (20–30%) but
share a common three-dimensional structure [21,22]. Tis-
sue distribution studies have revealed that a member of
this family 24p3 lipocalin (24p3) is mainly expressed in
the liver during an acute phase response [21]. It has also
been detected in spleen, lung and the uterus. In the latter
location, its expression has been found to be coincident
with parturition, a time of major tissue remodeling and
inflammation [22]. 24p3 has also been detected in the
conditioned media of LPS stimulated murine PU5.1.8
macrophages and therefore it has been suggested to func-
tion in defense against infectious agents [22]. However,
recent evidence proposed that the lipocalins may trigger
apoptosis in immune cells via an unknown cell surface
receptor [23]. SARS patients with respiratory distress fulfill
criteria for Acute Respiratory Distress Syndrome (ARDS)
and diffuse alveolar damage is seen in the lungs on histo-
logical examination of postmortem [24]. We speculate
that upregulation of lipocalins are part of the host
response in limiting unwanted tissue damage and in
reducing inflammation and lung fibrosis. In addition,
enhanced expression of lipocalins may play a role in the
potential cause of lymphopenia observed in the majority
of patients.
There is also up-regulation of expression of genes, such us,
Bactericidal Permeability Increasing Protein (BPI) and
Carcino Embryonic Antigen related Cell adhesion Mole-
cule 8 (CEACAM 8 or CD66b). BPI is released from acti-
vated neutrophils and is an endogenous antibiotic, which
rapidly kills Gram negative bacteria by high affinity bind-
ing to the LPS component of the cell wall [25]. CEACAM
8 is expressed by activated monocytes and granulocytes,
and significant up-regulation of this gene indicates the
involvement of innate immune cells in SARS. Other genes
which encode proteins like Leukotrien-B4 receptor
(LTB4R), Leukotrien-A4 hydrolase, IL-8 receptor (IL-
8RA), anaphylatoxin C3a receptor-1 (C3aR1), Neutrophil
Cytosolic Factor 1 (NCF 1), S100 calcium binding protein
A9, Defensin, (DEFA 1/4), LPS binding protein CAP18
(CAMP), and Peptidoglycan Recognition Protein
(PGLYRP) are involved in chemotaxis, inflammatory reac-
Table 2: Immune-response related genes which were found to be significantly down-regulated in PBMCs of SARS patients. Level of 
expression is expressed in Fold change (average of fold changes of ten patients, S1-S10) as compared to that of control samples from 
normal human subjects (C1-C4).
Genbank ID Description Gene name Fold change (S1-S10)
D13720.1 IL2-inducible T-cell kinase ITK 3.64
AF288571.1 Lymphoid enhancer factor-1 LEF1 3.63
NM_005356.1 Lymphocyte-specific protein 
tyrosine kinase
LCK 3.20
NM_003151.1 Signal transducer and activator of 
transcription 4
STAT4 3.14
BG435404 ADP-ribosylation factor-like 7 ARL7 2.99
J04132.1 T cell receptor zeta-chain CD3Z 2.96
BG532690 Alpha 4 subunit of VLA-4 receptor ITGA4 2.91
NM_001838.1 Chemokine (C-C motif) receptor 
7
CCR7 2.83
AI743792 Sialyltransferase 1 SIAT1 2.71
NM_001558.1 Interleukin 10 receptor, alpha IL10RA 2.71
BF669455 Sialomucin CD164 2.58
NM_000733.1 Epsilon polypeptide of CD3 CD3E 2.58
AI073984 Interferon consensus sequence 
binding protein 1
ICSBP1 2.48
NM_005475.1 Lymphocyte adaptor protein LNK 2.38
AB014560. Ras-GTPase activating protein SH3 
domain-binding protein 2
G3BP2 2.31
NM_004757.1 Small inducible cytokine subfamily 
E, member 1
SCYE1 2.19BMC Immunology 2005, 6:2 http://www.biomedcentral.com/1471-2172/6/2
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tion and superoxide metabolism [26]. Similarly, Formyl
Peptidase Receptor (FPR) genes are expressed by activated
neutrophils. Regulation of expression of FPR on
neutrophils plays a key role in neutrophil polarization
and chemotaxis. Chemotaxis is effected by a neutrophil
membrane mesh, via remodeling of the actin component
of the membrane [27]. Up-regulation of CD24 and
FcγR3A indicates some degree of neutrophil, B cell and NK
cell activity. FcγR3a, a low affinity receptor for IgG,
expressed in activated macrophages and NK cells, facili-
Table 3: Genes involved in homeostasis and cell growth, which were found to be significantly up-regulated in PBMCs of SARS patients. 
Level of expression is expressed in Fold change (average of fold changes of ten patients, S1-S10) as compared to that of control 
samples from normal human subjects (C1-C4).
Gen Bank ID Description Gene name Fold change (S1-S10)
BC005248.1 Eukaryotic translation initiation factor 1A EIF1AY 44.79
NM_001008.1 Ribosomal protein S4, Y-linked RPS4Y 20.75
NM_001062.1 transcobalamin I (vitamin B12 binding protein, R binder family) TCN1 16.88
NM_002357.1 MAX dimerization protein MAD 11.88
NM_012387.1 Peptidyl arginine deiminase, type V PADI4 9.12
NM_000184.1 Hemoglobin, gamma G HBG2 8.7
NM_000559.1 Hemoglobin, gamma A HBG1 8.1
NM_004653.1 SMC (mouse) homolog, Y chromosome SMCY 7.07
NM_002934.1 Ribonuclease, RNase A family, 2 RNASE2 5.99
M60721.1 Homeo box 1 HLX1 5.85
NM_005178.1 B-cell CLLlymphoma 3 BCL3 5.11
NM_001964.1 Early growth response 1 EGR1 4.9
NM_006931.1 Solute carrier family 2, member 3 SLC2A3 4.89
NM_002863.1 Phosphorylase, glycogen PYGL 4.89
NM_021122.2 Fatty-acid-Coenzyme A ligase, long-chain 2 FACL2 4.87
L13974.1 Nuclear factor (erythroid-derived) 2 NFE2 4.77
AI313324 H2A histone family, member O HIST2H2AA 4.48
BC002649.1 H1 histone family, member 2 HIST1H1C 4.44
AF073310.1 insulin receptor substrate-2 IRS2 4.43
NM_005330.2 hemoglobin, epsilon 1 HBE1 3.97
AF073890.1 Cathepsin X precursor CTSZ 3.69
AB002559.1 syntaxin binding protein 2 STXBP2 3.69
NM_017445.1 H2B histone family, member S HIST1H2BK 3.64
NM_003118.1 Secreted protein, acidic, cysteine-rich (osteonectin) SPARC 3.62
AL353759 Two genes for novel histone 1 HIST1H2AC 3.54
NM_003681.1 Pyridoxal (pyridoxine, vitamin B6) kinase PDXK 3.54
BC001886.1 Ribonucleotide reductase M2 polypeptide RRM2 3.53
AI082078 Actinin, alpha1 ACTN1 3.42
AF087942.1 Glycogenin-1L GYG 3.39
AL538601 Sjogren syndrome antigen A2 SSA2 3.36
NM_001805.1 CCAATenhancer binding protein CEBPE 3.26
NM_003528.1 H2B histone family, member Q HIST2H2BE 3.13
BC001906.1 Similar to metaxin 1 MTX1 3.11
NM_006755.1 Transaldolase 1 TALDO1 3.07
BC000893.1 Histone family, member A HIST1H2BK 3.06
AL161952.1 Glutamate-ammonia ligase GLUL 2.99
BC002842.1 H2B histone family, member B HIST1H2BD 2.78
NM_004219.2 Pituitary tumor-transforming 1 PTTG1 2.75
NM_012228.1 Pilin-like transcription factor PILB 2.73
L12711.1 Transketolase TKT 2.68
BE561479 Glyceraldehyde-3-phosphate dehydrogenase GAPD 2.61
NM_012331.2 Methionine sulfoxide reductase A MSRA 2.6
M33197 Glyceraldehyde-3-phosphate dehydrogenase GAPD 2.59
NM_005195.1 CCAAT enhancer binding protein CEBPD 2.57
NM_018840.1 Putative Rab5-interacting protein C20orf24 2.45
AA314406 Thyroid Hormone Receptor Associated protein TRAP95 2.44
NM_004832.1 Glutathione-S-transferase like; glutathione transferase omega GSTTLp28 2.42
NM_013272.2 Solute carrier family 21 (organic anion transporter) SLC21A11 2.42BMC Immunology 2005, 6:2 http://www.biomedcentral.com/1471-2172/6/2
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tates Antibody Dependent Cell mediated Cytotoxicity
(ADCC) by NK cells [13].
There is moderate up-regulation of the kappa light chain
of the Nuclear Factor (NFκB 1A) and the B-cell lymphoma
3-encoded protein (BCL3) (Table 1). The major form of
NFκB is a heterodimer of p65/p50 subunits, which regu-
lates expression of many proteins in activated immune
cells by binding to DNA. It interacts with NFκB through its
ankyrin repeats and it favors p50 dimerization by recruit-
ing p50 monomers from the cytoplasmic pool of p105/
p50 dimers, and thereby enhancing nuclear translocation
and DNA binding of p50 dimers [28]. BLC3 is expressed
by activated B cells and T cells on mitotic stimuli, playing
an important role in transcription activation [29].
In SARS patients there is down-regulation of genes (Table
2) which regulate proliferation and differentiation of T-
cells, such as the Lymphocyte-specific protein tyrosine
kinase (LCK), which is required for phosphorylation of
CD3. There is down-regulation of genes coding for the
epsilon polypeptide of the TCR (CD3E), IL-2 induced T-
cell kinase (ITK), the Zeta chain of the TCR (CD3Z), the
Alpha 4 subunit of VLA-4 receptor (ITGA4), the Chemok-
ine (C-C motif) Receptor 7 (CCR7), and the Interleukin
10 receptor alpha (IL10 RA). All these point to a potential
state of unresponsiveness towards the SARS-CoV antigens.
It has been described that T cell function in patients with
peritonitis had decreased Th1 function, without increased
Th2 response, and furthermore T cell proliferation and
cytokine secretion correlated with mortality [30]. In our
study, there is up-regulation of genes involved in homeos-
Real-Time PCR of selected genes Figure 2
Real-Time PCR of selected genes. PBMCs were isolated from 4 healthy volunteers (Control), from 10 SARS infected 
patients (SARS), and from 5 influenza virus infected patients (Influenza). Total RNA was extracted from all the samples and 
Light-Cycler Real-Time PCR was performed. The concentrations of these genes mRNA were calculated using respective stand-
ard curves. Lactoferrin expression (LTF); Lipocalin expression (Lipocalin); S100P expression (S100P); FCGR3A expression 
(FCGR3A); TLR2 expression (TLR2); Interferon Alpha expression (IFNa); Interferon Beta expression (IFNb); Interleukin 12-
p40 expression (IL-12); Tumor Necrosis Factor Alpha expression (TNFa); and GAPDH expression (GAPDH). Results are 
expressed as average ± SD of gene expression for each group (control n = 4; SARS n = 10; and influenza n = 5).
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tasis and cell growth (Table 3); for example, genes
involved in DNA synthesis, nucleosome assembly and
protein synthesis, such as, genes encoding Translation Ini-
tiation Factor 1A (EIF1 AY), and histone proteins. There is
down-regulation of genes coding for negative regulators
of the cell cycle, such as, Retinoblastoma-like 2 protein
(RBL2), Cyclin-Dependent Kinase Inhibitor 1B
(CDKN1B) and anti-apoptoic protein TNF induced pro-
tein GG2-1 etc (data not shown). These findings indicate
a high degree of proliferation of immune cells; however,
there is no significant level of increase in the expression of
cytokines like IL-2 or IL-3 and their receptors, which are
required for the proliferation and the differentiation of T
cells and effector functions of B cells and NK cells. So the
increased cell proliferation may be of a granulocyte line-
age rather than a monocytic lineage. We confirmed our
microarrays findings by Real time PCR on selected upreg-
ulated genes such as Lactoferrin Lipocalin, S100P,
FCGR3A, and TLR2 (Figure 2). The average expression of
all the five genes by real-time RT-PCR was compared to
the average expression levels found by microarray analysis
(Table 4). The real-time PCR method verified the results of
the gene array analysis and showed that those genes that
were up-regulated as determined by microarray analysis
were found to be up-regulated by real-time PCR analysis.
Moreover, since we did not find any upregulation of
cytokine-genes usually associated with a viral infection,
we selected a few cytokines and compared the SARS sam-
ples, with samples collected from 5 influenza virus-
infected patients. The observed results, in figure 2, showed
that in the influenza patients the mRNA for type I interfer-
ons (IFNα and IFNβ), TNFα and IL-12-p40 were upregu-
lated, whereas genes upregulated in the SARS patients
(LTF, Lipocalin, S100P, FGR3A and TLR2), were not
upregulated in the influenza patients. Therefore, firstly,
this confirms that cytokines usually triggered during a
viral infection were not detected in the SARS samples (but
were triggered in the influenza patients); and secondly,
genes triggered in the SARS patients were not triggered in
influenza patients.
In this study we have performed extensive analysis of gene
expression of PBMCs of SARS patients using a microarray
platform that includes more than 8000 gene sequences.
However, one potential drawback in our current experi-
mental design is that the gene expression levels were com-
pared between patient samples and normal controls using
PBMCs, rather than purified individual cell types. While it
would be of interest to determine the exact proportions of
monocytes, lymphocytes and contaminating granulocytes
in our PBMC preparations, unfortunately, given the
highly infective nature of patient samples and lack of suit-
able flowcytometry facility with appropriate bio-safety
control, FACS analysis was, however, not possible.
Our results suggest that the response of SARS affected
patients seems to be mainly an innate inflammatory
response, rather than a specific immune response against
a viral infection. There is no significant level of up-regula-
tion of MHC-I genes or major cytokines including IFNs
(α,β, and γ), or genes involved in complement mediated
cytolysis, suggesting that the immune response against the
SARS-CoV may be different from other viral infections, or
that the virus may be using a unusual strategy to evade the
host immune system and cause the pathogenesis and
mortality.
Conclusions
This differential gene expression profiling of PBMCs from
patients with SARS, strongly suggests that the response of
SARS affected patients seems to be mainly an innate
inflammatory response, rather than a specific immune
response against a viral infection. There is no significant
level of up-regulation of MHC-I genes or major cytokines,
including IFNs, or complement mediated cytolysis, sug-
gesting that the immune response against the SARS-CoV
may be different from other viral infections or that the
virus may be using a different strategy to evade the host
immune system and cause the pathogenesis and mortal-
ity. The severity of the disease does not seem to change the
genetic profile of the PBMCs: 5 of our patients were in
intensive care, whereas the other 5 patients did not
Table 4: Expression of microarray analysis compared with Real-time RT-PCR analysis
Gene name Microarray Realtime RT-PCR
Mean expression* Fold increase mRNA conc.(ng)* Fold increase
LTF 12403.95/83.78 148.05 1204/13 92.6
Lipocalin 9788/135.94 72 1455/25 58.2
FCGR3A 6202.81/1885.35 3.29 650/205 3.17
S100P 7496.57/292.49 25.63 475/45 10.5
TLR2 3459.33/1141.69 3.03 563/200 2.8
*Calculated as the average of 10 SARS samples over (/) the average of the 4 normal controls, and expressed as fold increase.BMC Immunology 2005, 6:2 http://www.biomedcentral.com/1471-2172/6/2
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require intensive care, at the time the blood was taken.
However, no substantial gene-expression differences were
observed that could correlate to disease severity. Moreo-
ver, we confirmed (by real-time-PCR) that cytokines usu-
ally associated with viral infections (such as interferons
and other cytokines) were not detected in the SARS sam-
ples, but were triggered in another viral infection (influ-
enza patients). We also showed that genes triggered in the
SARS patients were not triggered in the influenza patients.
Our study shows, for the first time, how the immune sys-
tem responds to the SARS infection and opens new possi-
bilities for designing new diagnostics and treatments for
this new life-threatening disease.
Methods
Patients and peripheral blood RNA extraction
Our study included ten adult patients (S1-S10) who were
diagnosed with SARS according to the World Health
Organization (WHO) SARS criteria and admitted to the
Tan Tock Seng Hospital, Singapore, for treatment and four
additional normal human subjects (C1-C4). Our protocol
was approved by the Tan Tock Seng Hospital Research
Ethics committee. Peripheral blood was collected by vein-
puncture of the brachial vein; mononuclear cells (PBMC)
were prepared using histopaque (Sigma- Aldrich, St.
Louis, MO) according to manufacturer's
recommendations. Sample preparation and processing
procedures were carried out as described in the Affymetrix
Gene Chip Expression Analysis Manual (Affymetrix Inc.,
Santa Clara, CA). Briefly, total RNA was extracted from
PBMCs, using Trizole method (Invitrogen, Carlsbad, CA)
and further purified using RNeasy columns according to
manufacturer's instructions (Qiagen, Valencia, CA). Integ-
rity of total RNA was confirmed by formamide gel electro-
phoresis and quantification was carried out by measuring
the A260 nm.
Generation of cDNA and labeled cRNA
5 µg of total RNA was used to synthesize double stranded
cDNA using T7-(dT24) oligonucleotide primer and Super-
script reverse transcriptase (Invitrogen). The resultant
cDNA was purified by phenol:chloroform extraction and
ethanol precipitation in presence of 7.5 M ammonium
acetate. 1 µg of purified cDNA was subsequently used to
synthesize biotin labeled cRNA by in vitro transcription
(IVT) using T7 RNA polymerase at 37°C for 5-6 hr as per
manufacturers' instructions (ENZO labeling kit, Ambion,
USA). Labeled cRNA obtained after IVT was purified using
RNeasy columns (Qiagen). Purified cRNA was fragmented
using fragmentation buffer (40 mmol/L Tris acetate, pH
8.1, 100 mmol/L Potassium acetate, 30 mmol/L Magne-
sium acetate) at 94°C for 35 min.
Microarray hybridization and scanning
Fragmented cRNA (10 to11µg/ probe array) was used to
hybridize to human focus array (HG-Focus Array) at 45°C
for 16 hr with constant rotation of 60 rpm in a Gene chip
hybridization oven 640 (Affymetrix). The chips were
washed and stained using Gene chip fluidics Station 400
(Affymetrix). Staining was performed using streptavidine
phycoerythrin conjugate (SAPE, Molecular Probes,
Eugene, OR), followed by the addition of biotinylated
antibody to streptavidine (Vector Laboratories, CA), and
finally with streptavidine phycoerythrin conjugate. Probe
arrays were scanned using Agilent Gene Array Scanner
Series US 74900593 (Agilent technologies, USA).
Data filtering and analysis
An absolute expression analysis was performed using
Microarray Suite Software 5.0 (Affymetrix) and relative
mRNA expression levels were expressed as plus or minus
fold changes compared to normal controls. Each chip was
scaled to an overall intensity of 500 to correct for minor
differences in overall chip hybridization intensity, and to
allow comparison between chips. The data from ~8700
genes was imported in to MicroDB 3.0 and Data Mining
Tool 3.0 (Affymetrix) for further analysis. Pearson Corre-
lation coefficient (r) was used to ensure the reproducibil-
ity of the data using signal from normal samples. T-test
was performed to identify genes that were differentially
expressed in SARS patients over normal samples. The sta-
tistical significance of the differential expression of any
gene was assessed by computing P value for each gene.
Any gene for which this P value was < 0.01 was considered
to be differentially expressed. We selected 186 genes for
further analysis that met the following criteria:
(i) Changes in expression of at least 2 fold higher or lower
comparing the normal
(ii) Signal >500
(iii) Detection P < 0.01 and
(iv) Genes which met the above criteria in at least 30% of
samples.
Finally, data representing 10 SARS patients fold changes
over control samples were averaged.
Genes were annotated according to biological process
using the Gene ontology: tool for the unification of
biology from the Gene Ontology Consortium [31]. The
complete set of raw data was deposited into the NCBIs'
Gene Expression Omnibus (GEO) and it can be accessed
through the GEO accession 'GSE1739' http://
www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE1739.BMC Immunology 2005, 6:2 http://www.biomedcentral.com/1471-2172/6/2
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Hierarchical clustering
Unweighted average linkage Hierarchical clustering was
applied for samples using the 'Genesis' software [32].
Genes with 'Present' call (P < 0.01) and significantly
changes in expression of at least 2 fold higher or lower
comparing the normal were selected. Finally 248 genes
which are passing this filter criteria in at least 15% of sam-
ples and above were selected for clustering.
Real-time quantitative PCR
Real-time PCR was performed for ten genes, namely:
Lactoferrin (Primers: 5' tcg tcc tgc tgt tcc tcg ggg 3' and 5'
tcc agc ggt cct gcg aag gcc 3'); Lipocalin (Primers: 5' aag ccc
ctg ctc ctg gcc atc agc 3' and 5' cga cct gat gct gta tgc cac gtg
3'); S100P (Primers: 5' cat gat cat aga cgt ctt ttc 3' and 5'
aca cga tga act cac tga agt 3'); TLR2 (Primers: 5' gta tct gca
agg gca gct cag gat 3' and 5' ttc ctc aag gaa ggt aag tcc agc
3'); FCGR3A (Primers: 5' ctc cgg ata tct ttg gtg act 3' and 5'
tgc aga gca gtg ttc ttc cag 3'); IFNA (Primers: 5'atg gcc ttg
acc ttt gct tt 3' and 5'tgg aag att tcc tca tag c 3'); IFNB (Prim-
ers: 5'atg acc aac aag tgt ctc ctc caa a 3' and 5' ttc ttc cag gac
tgt ctt ca 3'); IL-12 p40 (Primers: 5'atg tgt cac cag cag ttg gtc
atc 3' and 5'ctg aat gtc aaa tca gta ct 3'); TNFA (Primers:
5'gag tga caa gcc tgt agc cca tgt tgt agc 3' and 5'gca atg atc
cc a aag tag acc tgc cca gac 3'); GAPDH (Primers: 5'acc aca
gtc cat gcc atc ac 3' and 5'tcc acc acc ctg ttg ctg ta 3'). For
amplicon detection, the Light Cycler RNA Master SYBR
Green Kit (Roche) was used as described by the
manufacturer. PCRs were performed in a LightCycler®
instrument (Roche) as follows: reverse transcription at
61°C for 20 min, initial denaturation at 95°C for 2 min;
amplification for 45–65 cycles of denaturation (95°C, 5s,
ramp rate 2°C /s), annealing (optimal temperature, 5s,
ramp rate 2°C /s) and extension (72°C, product length
[bp]/25 s, ramp rate 2°C /s). A single online fluorescence
reading for each sample was taken at the end of extension
step. Quantitative results were expressed by identification
of the second derivative maximum points, which marked
the cycles where the second derivatives of the fluorescence
signal curves are at maximum. These points were
expressed as fractional cycle numbers. Then, these cycle
numbers were plotted against the logarithm of the con-
centrations of serially 2-fold diluted standard samples to
obtain a standard curve. The concentrations of unknown
samples were calculated by extrapolation from this stand-
ard curve. Positive sample specificity was confirmed by
determining the melting curve (95°C, 5s, ramp rate 20°C
/s; 68°C, 15s, ramp rate 20°C /s; 95 °C, 0s, ramp rate
0.1°C /s, continuous measurement).
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